Wegovy (semaglutide) has a list price of $1,349 per month — but that is not what most uninsured patients pay. Novo Nordisk’s self-pay programs, an oral pill launched in early 2026, and competing GLP-1 options from Eli Lilly have created a more complex cash-pay landscape than any single number captures. SunnyPharma breaks down every legitimate option for patients without insurance coverage in 2026.
Without insurance, the cheapest access to brand-name Wegovy is through NovoCare Pharmacy: $199/month for the first two fills of injections (intro offer through December 31, 2026), then $349/month. The oral pill starts at $149/month for lower doses (the 4 mg pill at that price through August 31, 2026), then $199–$299/month by dose. Uninsured patients with low income may qualify for Wegovy at no cost through Novo Nordisk’s Patient Assistance Program.
On Medicare? Stop here — there’s a cheaper path. If you have Medicare Part D, you can get Wegovy for a flat $50/month through the Medicare GLP-1 Bridge, which launched July 1, 2026 and beats every self-pay price on this page. This page is for people without insurance; if you’re on Medicare, see the Medicare GLP-1 Bridge guide instead. (Self-pay pricing below is also not available to anyone on Medicare, Medicaid, TRICARE, or VA coverage.)
Pricing dates to know — read before you fill: The NovoCare injection intro offer ($199/month for the 0.25 mg and 0.5 mg starter doses, first 2 monthly fills for new patients) runs through December 31, 2026. After the intro fills, all injection doses are $349/month. On the pill side, the $149/month price covers the 1.5 mg and 4 mg doses; the 4 mg pill holds that price only through August 31, 2026, after which 4 mg rises to $199/month. The 9 mg and 25 mg pill doses are $299/month at any time.
NovoCare Pharmacy — The Cheapest Brand-Name Option Without Insurance
NovoCare Pharmacy is Novo Nordisk’s direct-to-consumer dispensing service. For patients without insurance — or whose insurance does not cover Wegovy — it offers the lowest available brand-name price, well below retail pharmacies. You need a valid prescription; NovoCare handles fulfillment and delivery.
Wegovy Injection (Self-Pay via NovoCare)
| Tier | Doses | Monthly Cost | Notes |
|---|---|---|---|
| Intro (first 2 fills, through Dec 31, 2026) | 0.25 mg, 0.5 mg | $199 | New to the Wegovy Savings Offer or NovoCare Pharmacy. Two monthly fills. |
| Standard | All doses (0.25–2.4 mg) | $349 | Applies after the intro fills, and to all doses including maintenance 2.4 mg. |
| Wegovy HD 7.2 mg | 7.2 mg | $399 | Higher-dose pen. Standard self-pay, no intro pricing. |
Wegovy Pill (Self-Pay via NovoCare)
| Dose | Through Aug 31, 2026 | From Sep 1, 2026 | Notes |
|---|---|---|---|
| 1.5 mg tablet | $149/mo | $149/mo | Starter dose. Price unchanged after Aug 31. |
| 4 mg tablet | $149/mo | $199/mo | Intro offer on 4 mg expires Aug 31, 2026. |
| 9 mg tablet | $299/mo | $299/mo | No intro pricing at this dose. |
| 25 mg tablet | $299/mo | $299/mo | Maintenance dose. No intro pricing. |
To enroll: visit NovoCare.com or call 1-888-693-4686. Your prescriber submits the prescription directly. Home delivery is included. Self-pay pricing is not available to patients covered by government insurance programs (Medicare, Medicaid, TRICARE, VA).
Wegovy vs. Zepbound Without Insurance — Side-by-Side
If you are uninsured and considering a GLP-1 for weight loss, Wegovy (semaglutide) and Zepbound (tirzepatide) are the two FDA-approved injectable options. Both have manufacturer direct-pay programs that bring costs far below retail. The comparison matters because Zepbound’s LillyDirect program may offer a competitive price at higher doses.
| Wegovy (semaglutide) | Zepbound (tirzepatide) | |
|---|---|---|
| Manufacturer | Novo Nordisk | Eli Lilly |
| FDA approval (weight loss) | June 2021 | November 2023 |
| Self-pay program | NovoCare Pharmacy | LillyDirect |
| Self-pay price range | $149–$399/mo (by form and dose) | Confirm current pricing at LillyDirect.com |
| Pill available? | Yes — oral Wegovy launched early 2026 | No (injection only for self-pay) |
| Average weight loss (trials) | ~15% body weight (STEP trials, injection) | ~20%+ body weight (SURMOUNT trials) |
| Self-pay program notes | Pen device via mail; intro pricing with dates above | Single-dose vials require self-administration with syringe; requires valid Rx |
The decision between Wegovy and Zepbound for an uninsured patient is not purely cost-based — it involves your medical history, prescriber’s recommendation, and which drug your telehealth or clinic provider can prescribe. Because Eli Lilly adjusts LillyDirect self-pay pricing periodically, confirm Zepbound’s current monthly cost directly at LillyDirect.com before comparing. Discuss the full picture with your prescriber before choosing based on price alone.
Compounded Semaglutide Without Insurance
Compounded semaglutide from telehealth platforms runs $99–$400/month in 2026 — significantly cheaper than NovoCare’s brand-name pricing. It is legal when a licensed prescriber identifies a clinical basis for compounding (a specific dose not commercially available, or an added ingredient such as B12), and the pharmacy is a licensed 503A or 503B facility.[1]
What it is not: compounded semaglutide is not FDA-approved, not bioequivalence-tested against branded Wegovy, not covered by insurance, and not covered under the Medicare GLP-1 Bridge. The FDA has issued safety communications about dosing errors and sterility risks.[1]
To verify a compounding pharmacy before use: check the NABP searchable database at nabp.pharmacy. Only use telehealth services that require a real clinical evaluation — not questionnaire-only prescribing.
Important: The FDA declared the semaglutide shortage resolved in 2025. 503B outsourcing facilities can no longer compound copies of branded Wegovy under a shortage exemption. 503A pharmacies may still compound for patients with a documented personalization need — but the landscape for compounded GLP-1s has narrowed. Confirm current legal status with your prescriber before starting a compounded program.
Wegovy Patient Assistance Program — No Insurance, Low Income
Novo Nordisk operates a Patient Assistance Program (PAP) for uninsured patients who cannot afford Wegovy. If you qualify, you may receive medication at no cost. Eligibility is income-based — generally requiring household income at or below a defined percentage of the federal poverty level, no prescription drug coverage (including no Medicare or Medicaid drug benefit), and U.S. residency. Novo Nordisk adjusts the income threshold periodically.[2]
To apply: visit NovoCare.com or call 1-888-693-4686. Your prescriber must participate in the application. Eligibility typically runs 12 months with annual renewal. Confirm current income thresholds directly with Novo Nordisk at time of application — criteria change.
If you do not qualify for the PAP, additional assistance may be available through:
- NeedyMeds (needymeds.org) — tracks manufacturer PAPs and discount programs including Novo Nordisk’s current eligibility criteria
- RxAssist (rxassist.org) — independent PAP screener with eligibility verification
- Patient Advocate Foundation — case management for patients facing coverage denials or cost barriers
Does Medicaid Cover Wegovy? The 13 States — and How to Check Yours
If you are income-eligible for Medicaid, that may be a better first step than any self-pay program — but whether Medicaid covers Wegovy for weight loss depends entirely on your state. Every state Medicaid program is federally required to cover GLP-1s when prescribed for type 2 diabetes, and since 2024 for certain other indications (Wegovy for cardiovascular risk, Zepbound for sleep apnea). Coverage for obesity/weight loss specifically is optional, and most states do not offer it.
As of January 2026, 13 state Medicaid programs cover GLP-1s for obesity under fee-for-service — down from 16 in 2025, after California, New Hampshire, Pennsylvania, and South Carolina dropped coverage effective January 1, 2026.[9] The states publicly identified by KFF as covering GLP-1s for obesity treatment are:
- Delaware
- Kansas
- Michigan Restricted to morbid obesity
- Minnesota
- Mississippi
- Missouri
- North Carolina Reinstated Dec 2025
- Tennessee
- Utah
- Virginia Restricted to morbid obesity
- Wisconsin
That is 11 of the 13 states named directly in public KFF-sourced reporting; KFF counts 13 in total, and the two additional states are not individually enumerated in the public summaries. Because these lists change with state budgets — several states cut coverage on January 1, 2026, and others are debating changes — do not rely on a list alone. Confirm with your own state Medicaid office, which is the only authority on your current coverage.
How to check your state’s Medicaid coverage and apply:
1. Find your state’s Medicaid office. Every state runs its own program under its own name (Medi-Cal in California, TennCare in Tennessee, MO HealthNet in Missouri, MassHealth in Massachusetts, and so on). The official directory of all 50 states’ phone numbers and websites is at Medicaid.gov → “Where Can People Get Help With Medicaid & CHIP?” — select your state.
2. Ask two specific questions: “Does my Medicaid cover GLP-1 medications for weight loss / obesity?” and “If yes, what are the prior-authorization requirements?” Most covering states require prior authorization plus documentation of BMI and prior weight-loss attempts.
3. If you need federal help after contacting your state, the CMS Medicaid line is 877-267-2323 (TTY 866-226-1819). Your state office is always the first and primary contact for coverage questions.
One more path worth watching: the federal BALANCE Model lets states opt in to federally negotiated GLP-1 pricing for Medicaid starting in 2026, with participating states required to have coverage live by January 1, 2027.[9] If your state does not cover Wegovy for weight loss today, ask whether it is joining BALANCE — that is the most likely route to new coverage.
If you have Medicare (including alongside Medicaid): the separate Medicare GLP-1 Bridge gives eligible Part D members Wegovy for a flat $50/month through December 31, 2027 — often the lowest-cost route of all for anyone with Medicare drug coverage.
Retail Pharmacy Cash Prices — Why They Are Not Your Best Option
At a standard retail pharmacy (CVS, Walgreens, Rite Aid), Wegovy’s cash price runs roughly $1,200–$1,650/month depending on location, even with GoodRx coupons. GoodRx reduces the retail price by roughly 10% but cannot bring it close to NovoCare direct pricing.
The reason to use a retail pharmacy despite the higher cost: same-day local pickup. If you need a fill urgently and cannot wait for NovoCare’s mail delivery, a retail pharmacy with a GoodRx coupon is the fastest option. In all other circumstances, NovoCare direct ($349/month for injections after the intro fills) is significantly cheaper.
GoodRx and NovoCare direct cannot be combined. They are separate programs — using one means the other does not apply.
Frequently Asked Questions
How much does Wegovy cost without insurance in 2026?
Without insurance, Wegovy’s retail list price is $1,349/month. Through NovoCare Pharmacy (Novo Nordisk’s direct program), uninsured patients pay $199/month for the first two injectable fills of the 0.25 mg and 0.5 mg starter doses (intro offer through December 31, 2026), then $349/month for all doses. The oral pill starts at $149/month for lower doses, rising to $199–$299/month at higher doses. Low-income uninsured patients may qualify for the Novo Nordisk PAP at no cost.
What is the cheapest way to get Wegovy without insurance?
The cheapest legitimate options in order: (1) Novo Nordisk PAP — $0 for qualifying low-income uninsured patients; (2) NovoCare pill — $149/month for lower doses; (3) NovoCare injection — $199/month intro (first 2 fills through December 31, 2026), then $349/month; (4) Compounded semaglutide — $99–$400/month but not FDA-approved. Retail pharmacy cash prices (roughly $1,200–$1,650/month even with GoodRx) are significantly higher than NovoCare direct.
When does the NovoCare intro price end in 2026?
For injections, new patients pay $199/month for the first two monthly fills of the 0.25 mg and 0.5 mg starter doses through December 31, 2026, then $349/month for all doses. For the pill, the $149/month price covers the 1.5 mg and 4 mg doses; the 4 mg pill holds that price only through August 31, 2026, then rises to $199/month. The 9 mg and 25 mg pill doses are $299/month at any time. Novo Nordisk reserves the right to modify these programs.
Is Wegovy or Zepbound cheaper without insurance?
Both have manufacturer self-pay programs — NovoCare Pharmacy for Wegovy and LillyDirect for Zepbound. Wegovy’s pill ($149/month at starter doses) is its lowest-cost form, and its injection runs $199/month intro then $349/month. Eli Lilly adjusts LillyDirect pricing periodically, so confirm Zepbound’s current monthly cost at LillyDirect.com before comparing. The right choice depends on your clinical profile — discuss with your prescriber.
Can I get Wegovy for free without insurance?
Potentially — through Novo Nordisk’s Patient Assistance Program. Qualifying uninsured patients with low income and no prescription drug coverage may receive Wegovy at no cost. Contact NovoCare at 1-888-693-4686 or visit novocare.com. Your prescriber must be involved in the application. NeedyMeds (needymeds.org) and RxAssist (rxassist.org) can also help you identify your eligibility and navigate the application process.
How much does the Wegovy pill cost without insurance?
Through NovoCare Pharmacy: $149/month for the 1.5 mg and 4 mg doses (the 4 mg pill rises to $199/month after August 31, 2026). The 9 mg and 25 mg maintenance doses are $299/month at any time. The pill is taken daily on an empty stomach 30 minutes before the first food, drink, or other oral medication of the day. No refrigeration needed. At retail pharmacies without NovoCare, the pill’s cash price tracks near the injection’s retail price — significantly higher than NovoCare direct.
Is compounded semaglutide a safe alternative to Wegovy without insurance?
Compounded semaglutide is legal under specific circumstances — a licensed 503A pharmacy with a prescriber-identified personalization need — and runs $99–$400/month, making it the cheapest available option by price. It is not FDA-approved, not bioequivalence-tested against Wegovy, and not covered by insurance. The FDA has issued safety alerts about dosing errors and sterility risks. If you choose a compounded option, verify the pharmacy at nabp.pharmacy and only use services requiring a real clinical evaluation. With the semaglutide shortage now resolved, the legal basis for some compounded programs has narrowed — confirm current status with your prescriber.
Can I use GoodRx for Wegovy without insurance?
Yes, but it is not your best option in most cases. GoodRx coupons reduce Wegovy’s retail price by roughly 10% — to about $1,200–$1,650/month depending on pharmacy and location. NovoCare direct ($349/month for injections after the intro fills, $149–$299/month for the pill) is significantly cheaper. GoodRx and NovoCare cannot be combined. The main reason to use GoodRx is same-day local pharmacy pickup if you cannot wait for NovoCare mail delivery.
Does Medicaid cover Wegovy for weight loss, and in which states?
It depends on your state. Medicaid must cover GLP-1s for type 2 diabetes everywhere, but coverage for weight loss is optional. As of January 2026, 13 state Medicaid programs cover GLP-1s for obesity under fee-for-service — down from 16 in 2025. States publicly identified by KFF include Delaware, Kansas, Michigan (morbid obesity only), Minnesota, Mississippi, Missouri, North Carolina, Tennessee, Utah, Virginia (morbid obesity only), and Wisconsin. Because lists change with state budgets, confirm with your own state Medicaid office — find its number in the Medicaid.gov state directory, or call the federal CMS line at 877-267-2323 after contacting your state. If your state does not cover it, ask whether it is joining the federal BALANCE Model, which expands Medicaid GLP-1 access in participating states.
How we reviewed this article:
Self-pay pricing was verified directly against Novo Nordisk’s NovoCare Pharmacy program terms and NovoCare Savings Offer pages in July 2026. Medicaid state-coverage counts and the state list are drawn from KFF’s “Medicaid Coverage of and Spending on GLP-1s” (January 2026) as reported by KFF and Stateline. State Medicaid contact routing is from Medicaid.gov. Compounded semaglutide legal status is from FDA safety communications and NABP guidance. We use only primary or institutional sources and update pricing on a rolling basis as manufacturer and state programs change.
Read our editorial policy →Sources & References
- FDA. Safety Communication: Dosing Errors with Compounded Injectable Semaglutide Products. 2025. fda.gov
- Novo Nordisk. Patient Assistance Program — NovoCare. 2026. novocare.com
- Novo Nordisk. Wegovy Savings Offer & Self-Pay Pricing. July 2026. novocare.com
- Novo Nordisk. Wegovy Cost, Coverage & List Price ($1,349.02/package). 2026. novocare.com
- GoodRx. Wegovy Prices and Coupons 2026. goodrx.com
- Eli Lilly. LillyDirect Zepbound Self-Pay Pricing. lillydirect.com
- NABP. Verified Pharmacy Program. 2026. nabp.pharmacy
- Medicaid.gov. Where Can People Get Help With Medicaid & CHIP? (state contact directory). medicaid.gov
- KFF. Medicaid Coverage of and Spending on GLP-1s. January 2026. kff.org